Healthcare -
Biotechnology - NASDAQ - US
$ 3.345
1.36 %
$ 634 M
Market Cap
-7.78
P/E
Price Target
Average
--100.00%
Revenue Forecast
Estimate
45.96%
EBIT
Estimate
10.28%
Net Income
Estimate
19.38%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
Arbutus Biopharma Corporation
ABUS has no price targets from Wall Street.
REVENUE FORECAST
Revenue Forecast Chart ABUS
EBIT FORECAST
EBIT Forecast Chart ABUS
NET INCOME FORECAST
Net Income Chart ABUS